RSV-IGIV

respiratory syncytial virus immune globulin (RSV-IGIV)

an immune serum.
indications It is used in children less than 2 years of age with bronchopulmonary dysplasia or in those born prematurely to prevent serious lower respiratory tract infection caused by respiratory syncytial virus.
contraindications Factors that prohibit its use are hypersensitivity to this drug or to other human immunoglobulin preparations and IgA deficiency.
adverse effects Life-threatening effects are respiratory distress, hypoxia, anaphylaxis, and angioneurotic edema. Other adverse effects are tachypnea, rales, wheezing, fever, hypertension, tachycardia, fluid overload, diarrhea, gastroenteritis, vomiting, rash, overdose effect, and inflammation at the injection site.

RSV-IGIV

Abbreviation for respiratory syncytial virus immune globulin intravenous.
References in periodicals archive ?
Some concerns that restrict the use of RSV-IGIV include (1) monthly IV infusions lasting several hours each, (2) increased fluid volume and protein loads necessitating occasional use of diuretics, (3) theoretical concerns for transmission of blood-borne pathogens, and (4) the potential for polyclonal immunoglobulin interference with the immune response to vaccination.
Preventions of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV.
currently markets its first product, CytoGam(R) (Cytomegalovirus Immune Globulin Intravenous (Human), (CMV-IGIV); see full prescribing information), through its own hospital-based sales force and, in addition to a product under review by the FDA, RSV-IGIV, has six other product candidates in clinical trials.
MedImmune currently markets its first product, CytoGam( (Cytomegalovirus Immune Globulin Intravenous (Human), please see package insert attached for full prescribing information), through its own hospital-based sales force and in addition to a product under FDA review, RSV-IGIV, has six other product candidates in clinical trials.
This agreement is part of our ongoing effort to reduce per unit production cost for CytoGam(R) and also provides MedImmune with increased filling and packaging capacity to support both CytoGam(R) and RSV-IGIV until our proposed manufacturing facility can be completed," commented David M.
MedImmune currently markets its first product, CytoGam(R) (Cytomegalovirus Immune Globulin Intravenous (Human), please see package insert attached for full prescribing information), through its own hospital-based sales force and in addition to a product under FDA review, RSV-IGIV, has six other product candidates in clinical trials.
RSV-IGIV was recently recommended for approval by an FDA advisory committee.
RSV-IGIV is a specific immune globulin enriched in antibodies against the respiratory syncytial virus (RSV).
The BPAC recommended RSV-IGIV for prevention of RSV disease in children under 24 months with a chronic lung disease called bronchopulmonary dysplasia or a history of premature birth.